Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
63%
Antiretroviral Therapy
44%
HIV Transmission
20%
Early Antiretroviral Therapy
14%
Reservoir Size
13%
HIV Reservoir
13%
Latent Reservoir
12%
Highly Active Antiretroviral Therapy (HAART)
11%
Viremia
11%
Perinatal Infection
11%
United States
11%
Resting CD4+ T Cells
10%
Nevirapine
10%
Remission
9%
Virus
9%
People Living with HIV (PLHIV)
9%
Viral Reservoir
9%
HIV DNA
8%
HIV Cure
8%
Immune Activation
8%
CD4+ T Cells
8%
AIDS/HIV
8%
Viral Load
8%
Cabotegravir
8%
Pharmacokinetics
8%
Older Adults
7%
Proviral Reservoirs
7%
Antiretroviral
7%
HIV RNA
7%
Neonate
7%
T Cells
7%
Early Treatment
6%
HIV Infection
6%
African children
6%
Latent HIV Reservoir
6%
Combined Antiretroviral Therapy (cART)
6%
HIV Patients
6%
Proof of Concept Study
6%
Infected children
6%
Human Immunodeficiency Virus Infection
5%
Virologic Control
5%
Low-level Viremia
5%
Cisgender
5%
Combination Therapy
5%
Single Center
5%
Scientific Strategies
5%
Support Initiatives
5%
Breastfeeding Support
5%
Human Immunodeficiency Virus Prevention
5%
DNA Decay
5%
Immunology and Microbiology
Human Immunodeficiency Virus 1
96%
Human Immunodeficiency Virus
68%
Blood Plasma
25%
Drug Resistance
22%
T-Helper Cell
21%
Viremia
21%
Human Immunodeficiency Virus Infection
15%
Viral Load
14%
Reverse Transcriptase
12%
Genotype
11%
Dynamics
11%
Monospecific Antibody
8%
Cytokine
8%
Virus Type
7%
Provirus
7%
T Cell
7%
Wild Type
6%
CD4
5%
Lymphocyte Transformation
5%
COVID-19
5%
CD4 Lymphocyte Count
5%
Peripheral Blood Mononuclear Cell
5%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
35%
Infection
22%
Human Immunodeficiency Virus Infection
19%
Human Immunodeficiency Virus 1
19%
Highly Active Antiretroviral Therapy
15%
Viremia
15%
Drug Resistance
14%
Nevirapine
13%
T-Helper Cell
12%
Aciclovir
10%
Pediatrics
9%
Adolescent
9%
Resistance Mutation
8%
Genotype
7%
Proteinase Inhibitor
6%
Arm
5%
Transgender
5%
Cabotegravir
5%
Cerebrospinal Fluid
5%
Serositis
5%
COVID-19
5%
Biological Marker
5%